Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated With Dementia Due to Alzheimer ’s Disease

PRINCETON, N.J. and TOKYO, JAPAN February 12, 2024– Otsuka Pharmaceutical Development& Commercialization, Inc., (OPDC) and our parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce topline results of the phase 3 clinical trial...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials